The purpose of this study was to evaluate the association of expression of ${alpha}5{eta}1$-integrin with clinicopathologic features and prognosis in cervical cancer. Levels of ${alpha}5{eta}1$-integrin in normal cervical mucosa and cervical cancer tissue were detected with immunohistochemistry. Survival analysis by the Kaplan-Meier method was performed to assess prognostic significance. ${alpha}5{eta}1$-integrin expression was detected in 84.6% (143/169) cervical cancer samples, significantly different from that in normal cervical mucosa (P < 0.05). Positive expression rates of ${alpha}5{eta}1$-integrin in patients with poor histologic differentiation, lymph node metastasis, and recurrence were elevated. Using Kaplan-Meier analysis, a comparison of survival curves of low versus high expression of ${alpha}5{eta}1$-integrin revealed a highly significant difference in human cervical cancer cases (P < 0.05), suggesting that overexpression of ${alpha}5{eta}1$-integrin is associated with a worse prognosis.The ${alpha}5{eta}1$-integrin promotes angiogenesis and associates with lymph node metastasis, vascular invasion and poor prognosis of cervical cancer. The current study indicated that ${alpha}5{eta}1$-integrin may be an independent prognostic factor for cervical cancer patients.